





PTO/SB/08A		<div style="text-align: center;">  </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/839,424
		Filing Date	04-20-2001
		Confirmation Number	1761
		First Named Inventor	D. Brown
		Group Art Unit	1614 1625
		Examiner Name	TBA
Sheet	1 of 8	Attorney Docket No.	3364(PHA 4176)





U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
BMR	1	4,146,721	B1	Rainer	03-27-1979
	2	4,822,805	B1	Takasugi et al.	04-18-1989
	3	4,914,121	B1	Sawai et al.	04-03-1990
	4	5,051,518	B1	Murray et al.	09-24-1991
	5	5,134,142	B1	Matsuo et al.	07-28-1992
	6	5,338,749	B1	Wuest et al.	08-16-1994
	7	5,344,991	B1	Reitz et al.	09-06-1994
	8	5,380,738	B1	Norman et al.	01-10-1995
	9	5,387,592	B1	Bradbury et al.	02-07-1995
	10	5,389,635	B1	Olson	02-14-1995
	11	5,393,790	B1	Reitz et al.	02-28-1995
	12	5,401,765	B1	Lee	03-28-1995
	13	5,418,254	B1	Huang et al.	05-23-1995
	14	5,420,287	B1	Reitz et al.	05-30-1995
BMR	15	5,434,178	B1	Talley et al.	07-18-1995






Examiner Signature	<i>Berta Robinson</i>	Date Considered	1 / 27 / 02
--------------------	-----------------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		<div style="text-align: center;">   </div>		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/839,424		
		Filing Date	04-20-2001		
		Confirmation Number	1761		
		First Named Inventor	D. Brown		
		Group Art Unit	1614 162500		
		Examiner Name	TBA		
Sheet	2	of	8	Attorney Docket No.	3364(PHA 4176)

BMR	16	5,466,823	B1	Talley et al.	11-14-1995
	17	5,475,018	B1	Lee et al.	12-12-1995
	18	5,486,534	B1	Lee et al.	01-23-1996
	19	5,504,215	B1	Talley et al.	04-02-1996
	20	5,508,426	B1	Talley et al.	04-16-1996
	21	5,510,496	B1	Talley et al.	04-23-1996
	22	5,516,907	B1	Talley et al.	05-14-1996
	23	5,521,193	B1	Flynn et al.	05-28-1996
	24	5,521,207	B1	Graneto	05-28-1996
	25	5,534,521	B1	Flynn et al.	07-09-1996
	26	5,565,482	B1	Talley et al.	10-15-1996
	27	5,576,339	B1	Huang et al.	11-19-1996
	28	5,596,008	B1	Lee	01-21-1997
	29	5,616,601	B1	Khanna et al.	04-01-1997
	30	5,639,777	B1	Lee	06-17-1997
	31	5,663,180	B1	Reitz et al.	09-02-1997
	32	5,668,161	B1	Talley et al.	09-16-1997
	33	5,670,510	B1	Huang et al.	09-23-1997
	34	5,672,626	B1	Huang et al.	09-30-1997
BMR	35	5,672,627	B1	Huang et al.	09-30-1997

Examiner Signature	<i>Brent Robinson</i>	Date Considered	1/27/02
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/839,424	
			Filing Date	04-20-2001	
			Confirmation Number	1761	
			First Named Inventor	D. Brown	
			Group Art Unit	1614/1625	
			Examiner Name	TBA	
Sheet	3	of	8	Attorney Docket No.	3364(PHA 4176)

BMR	36	5,719,163	B1	Norman et al.	02-17-1998
	37	5,736,579	B1	Reitz et al.	04-07-1998
	38	5,739,166	B1	Reitz et al.	04-14-1998
	39	5,756,529	B1	Isakson et al.	05-26-1998
	40	5,760,068	B1	Talley et al.	06-02-1998
	41	5,859,036	B1	Sartori et al.	01-12-1999
	42	5,859,257	B1	Talley	01-12-1999
	43	5,886,016	B1	Talley et al.	03-23-1999
	44	5,908,852	B1	Talley et al.	06-01-1999
	45	5,916,905	B1	Weier et al.	06-29-1999
	46	5,932,598	B1	Talley et al.	08-03-1999
BMR	47	5,935,990	B1	Khanna et al.	08-10-1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
**	48	EP	197704	A2	GEC Avionics Limited	10-15-1986	
**	49	EP	26928	A1	GDG Life Sciences Inc.	04-15-1984	
**	50	EP	745396	A1	Japan Tobacco, Inc.	12-04-1996	

Examiner Signature	<i>Brent A. Johnson</i>	Date Considered	11/27/02
--------------------	-------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/839,424
		Filing Date	04-20-2001
		Confirmation Number	1761
		First Named Inventor	D. Brown
		Group Art Unit	1614 1025
		Examiner Name	TBA
Sheet	4	of	8
		Attorney Docket No.	3364(PHA 4176)

51	EP	799823	A1	Sankyo Company Limited	10-08-1997
52	GB	2294879	A	Merck & Co Inc.	05-15-1996
53	JR	1045374	A	Kokusai Shiyaku KK (abstract)	02-17-1989
54	JP	4277724	A	Sumitomo Electric Ind. Ltd.	10-02-1992
55	JP	5323522	A	Fuji Photo Film Co Ltd.	12-07-1993
56	WO	92/05162	A1	Taiho Pharmaceutical Co., Ltd.	04-02-1992
57	WO	92/19604	A1	Taiho Pharmaceutical Co., Ltd.	11-12-1992
58	WO	93/14082	A1	Smith-Kline Beecham Corporation	07-22-1993
59	WO	94/13635	A1	Merck Frosst Canada Inc.	06-23-1994
60	WO	94/15932	A1	G.D. Searle & Co.	07-21-1994
61	WO	94/20480	A1	Merck Frosst Canada Inc.	09-15-1994
62	WO	94/26731	A1	Merck Frosst Canada Inc.	11-24-1994
63	WO	95/00501	A2	Merck Frosst Canada Inc.	01-05-1995
64	WO	95/30652	A1	G.D. Searle & Co.	11-16-1995
65	WO	95/30656	A1	G.D. Searle & Co.	11-16-1995
66	WO	96/03387	A1	G.D. Searle & Co.	02-08-1996
67	WO	96/03388	A1	G.D. Searle & Co.	02-08-1996
68	WO	96/09293	A1	G.D. Searle & Co.	03-28-1996
69	WO	96/19462	A1	Japan Tobacco Inc. (abstract)	06-27-1996
70	WO	96/19463	A1	Japan Tobacco Inc. (abstract)	06-27-1996

Examiner Signature	<i>Kinto Roberson</i>	Date Considered	1/27/02
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/839,424	
			Filing Date	04-20-2001	
			Confirmation Number	1761	
			First Named Inventor	D. Brown	
			Group Art Unit	1614	
			Examiner Name	TBA	
Sheet	5	of	8	Attorney Docket No.	3364(PHA 4176)

71	WO	96/36617	A1	G.D. Searle & Co.	11-21-1996
72	WO	96/37476	A1	G.D. Searle & Co.	11-28-1996
73	WO	97/16435 ✓	A1	Merck Frosst Canada Inc.	05-09-1997
74	WO	97/25045 ✓	A1	SmithKline Beecham Corporation	07-17-1997
76	WO	97/25047 ✓	A1	SmithKline Beecham Corporation	07-17-1997
76	WO	97/25048 ✓	A1	SmithKline Beecham Corporation	07-17-1997
77	WO	98/03484 ✓	A1	Merck Frosst Canada Inc.	01-29-1998
78	WO	98/07425 ✓	A1	SmithKline Beecham Corporation	02-26-1998
79	WO	98/11080	A1	Laboratories UPSA	03-19-1998
80	WO	98/22442 ✓	A1	Angelini Recherche S.p.A.	05-28-1998
81	WO	98/47890	A1	G.D. Searle & Co.	10-29-1998
82	WO	99/14205	A1	Almirall Prodesfarma SA	03-25-1999
83	WO	99/64415	A1	Pfizer Inc.	12-16-1999

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	84	NASJLETTI, A. "The Role of Eicosanoids in Angiotensin-Dependent Hypertension." Hypertension, 1998, pp. 194-200, Vol. 31, No. 1, Part 2..	
	85	AHLUWALIA, et al., "Mechanism of the Debromination in Heteocyclization Using a a-Dibromocarbonyl Compounds as Synthons." Synth. Commun., 1989, pp. 619-626, Vol. 19, Nos. 3&4.	

Examiner Signature	<i>[Signature]</i>	Date Considered	11/27/02
--------------------	--------------------	-----------------	----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/839,424
		Filing Date	04-20-2001
		Confirmation Number	1761
		First Named Inventor	D. Brown
		Group Art Unit	1644
		Examiner Name	TBA
Sheet	6	of	8
		Attorney Docket No.	3364(PHA 4676)


86	MUKERJEE et al., "Synthesis of Some Formazans and tetrazolium salts as antiviral agents." Acta. Pharma. Jugosl., 1981, pp. 151-158, Vol. 31.
87	SPEIR et al., "Aspirin Attenuates Cytomegalovirus Infectivity and Gene Expression Mediated by Cyclooxygenase-2 in Coronary Artery Smooth Muscle Cells." Circ. Res., 1998, pp. 210-216, Vol. 83, No. 2.
88	BAGETTA et al., "HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-Oxygenase Type 2 (Cox-2)." Biochem. Biophys. Res. Commun., 1998, pp. 819-824, Vol. 244.
89	DOROFENKO et al., Khim. Farm. Zh., 1982, pp. 920-921, Vol. 16.
90	GIERSE et al., "Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase." J. Biochem, 1995, pp. 479-484, Vol. 305, Part 2.
91	BOSCH, et al., "Efficacy and Tolerability of Intramuscular and Oral Meloxicam in Patients with Acute Lumbago: A Comparison with Intramuscular and Oral Piroxicam." Curr. Med. Res. Opin., 1997, pp 29-38, Vol. 14, No. 1.
92	FAID-ALLAH et al., "Pyrazole Derivatives with Possible Hypoglycemic Activity." Ind. J. Chem., 1988, pp. 245-249, Vol. 27.
93	HARGREAVES et al., "A New and Sensitive Method for Measuring thermal Nociception in Cutaneous Hyperalgesia." Pain, 1988, pp. 77-88, Vol. 32.
94	HUANG, et al., "A Novel One-Pot Conversion of Methyl Sulfones to Sulfonamides." Tetrahedron Letters, 1994, pp. 7201-7204, Vol. 35, No. 39.
95	SINGER et al., "Cyclooxygenase 2 Is Induced in Colonic Epithelial Cells in Inflammatory Bowel Disease." Gastroenterology, 1998, pp. 297-306, Vol. 115, No. 2.
96	MIYAMOTO et al., "The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis." Neuro Report, 1998, pp. 2331-2334, Vol. 9, No. 10.
97	SUBBARAMAIAH et al., "Inhibition of Cyclooxygenase: A Novel Approach to Cancer Prevention (44170)." Proc. Soc. Exp. Biol. Med., 1997, pp. 201-210, Vol. 216, No. 2.

Examiner Signature		Date Considered	1/27/02
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		<div style="text-align: center;">  </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/839,424
		Filing Date	04-20-2001
		Confirmation Number	1761
		First Named Inventor	D. Brown
		Group Art Unit	1614 / 162500
		Examiner Name	TBA
Sheet	7	of	8
		Attorney Docket No.	3364(PHA 4176)

	98	WILSON, et al., "Increased Expression of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Barrett's Esophagus and Associated Adenocarcinomas." Cancer Res., 1998, pp. 2929-2934, Vol. 58, No. 14.	
	99	KHARASCH, et al., "Derivatives of Sulfenic Acids. V. I-Fluorenone Sulfur Compounds." Am. Chem. Soc., 1951, pp. 3240-3244, Vol. 73, No. 7.	
	100	BUSTOS, et al., "Modulation of Eicosanoid Metabolism in Endothelial Cells in a Xenograft Model." J. Clin. Invest., 1997, pp 1150-1158, Vol. 100, No. 5.	
	101	SHOUP, et al., "Cyclooxygenase-2 Inhibitor NS-398 Improves Survival and Restores Leukocyte Counts in Burn Infection." J. Trauma: Inj. Infect., Crit Care, 1998, pp 215-221, Vol. 45, No. 2.	
	102	TSUJII et al., "Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells." Cell, 1998, pp. 705-716, Vol. 93, No. 5.	
	103	BARNES et al., "Cyclooxygenase-2 Expression in Airway Cells." Lung Biol. Health Dis, 1998, pp. 111-127, Vol. 114.	
	104	REID, et al., "Some New β -Diketones Containing the Trifluoromethyl Group." J. Amer. Chem. Soc., 1950, pp 2948-2952, Vol. 72, No. 7.	
	105	BUCKMAN et al., "Cox-2 Expression is Induced by UVB Exposure in Human Skin: Implications for the development of skin cancer." Carcinogenesis, 1998, pp. 723-729, Vol. 19, No. 5.	
	106	NOGAWA et al., "Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia." Proc. Natl. Acad. Sci., 1998, pp. 10966-10971, Vol. 95, No. 18.	
	107	DIKSHIT, et al., "Synthesis and biological activity of 2,3- and 3,4-diarylfurans and 2,3,4-triaryl-2,5-dihydrofurans." Indian J. Chem, Sect. B, 1990, pp 954-960, Vol. 29B, No. 10.	
	108	MIYAURA, et al., "The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases." Synth. Commun., 1981, pp. 513-519, Vol. 11, No. 7.	
	109	HIDA et al., "Non-small Cell Lung Cancer Cyclooxygenase Activity and Proliferation and Inhibited by Non-steroidal Antiinflammatory Drugs." Anticancer Res., 1998, pp. 775-782, Vol. 18, No. 1A.	


Examiner Signature	<i>Rinto Robinson</i>	Date Considered	11/27/02
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED
 DEC 3 2001
 TC 1700
 RECEIVED
 DEC 5 2001

PTO/SB/08A		<div style="text-align: center;">  </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/839,424
		Filing Date	04-20-2001
		Confirmation Number	1761
		First Named Inventor	D. Brown
		Group Art Unit	1614 / 16290
		Examiner Name	TBA
Sheet	8	of	8
		Attorney Docket No.	3364(PHA 4176)

110	KAWAMORI et al., "Chemopreventive Activity of Celecoxib, a Specific Cyclooxygenase-2 Inhibitor, against Colon Carcinogenesis." Cancer Res., 1998, pp. 409-412, Vol. 58, No. 3.
111	SANDHYA et al., "A light and electron microscopic study of cytoplasmic phospholipase A ₂ and cyclooxygenase-2 in the hippocampus after kainate lesions." Brain Res., 1998, pp. 223-231, Vol. 788.
112	CHU, et al., "Synthesis of Sodium androst-5-ene-17-one-3 β -methylene sulfonate." Steroids, 1997, pp 543-545, Vol. 62.
113	VLEESCHAUWER, et al., "Remarkably Mild and Simple Preparations of Sulfinates, Sulfonyl Chlorides and Sulfonamides from Thioanisoles." Syn. Lett., 1997, pp. 375-377, Vol. 4.
114	WINTER et al., "Carrageenin-Induced Edema in Hind Paw of the Rat as an Assay from Antiinflammatory Drugs." Proc. Soc. Exp. Biol. Med., 1962. pp. 544-547, Vol. 111.

RECEIVED
 DEC 05 2001
 TECH CENTER 1600/2900

Examiner Signature	<i>Binto Robinson</i>	Date Considered	11/27/02
--------------------	-----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.